Compare ConocoPhillips (COP) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs BIO-TECHNE Corp — how do they compare? ConocoPhillips trades at $125.7 (market cap $151.27B), while BIO-TECHNE Corp trades at $72.19 (market cap $11.24B). The key difference: ConocoPhillips is far larger — about 13.5× BIO-TECHNE Corp's market cap, and ConocoPhillips pays the higher dividend (2.67%). Which is the better fit depends on your goals.
| COP | TECH | |
|---|---|---|
Market Cap | $151.27B | $11.24B |
Sector | Energy | Health |
52-Week High | $133.80 | $72.29 |
52-Week Low | $85.66 | $43.31 |
Enterprise Value | $166.87B | $11.32B |
Dividend Yield | 2.67% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $123.03, up 4.61% on the day, with a bullish technical signal from moving averages and strong Q2 2026 earnings beats. The company reported EPS of $3.24 versus $2.90 expected, driven by higher oil prices and Permian Basin output. Recent CEO transition to Andy O'Brien signals continuity, with a consensus analyst price target of $150.00 indicating 22% upside potential.
Outlook remains positive due to robust free cash flow growth and favorable commodity trends, though risks include oil price volatility and execution of the Alaska project. The stock offers value with a P/E of 16.66 and a net income margin of 14.65%, supported by a 74.51% buy rating from analysts.
Bio-Techne (TECH) trades at $72.11, down 0.01% on the day, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q2 2026. The company reported Q4 2026 revenue of $321.2 million, with organic growth of 3%, and declared a $0.08 dividend. However, net income margin has declined from 25.09% in 2023 to 6.01% in 2025, and valuation ratios like P/E of 103.09 remain elevated.
The outlook is mixed: strong cash flow and institutional interest support upside, but high valuation and margin compression pose risks. Analysts are evenly split between Buy and Hold, with a consensus price target of $71.67, slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
